Overview

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
0
Participant gender:
All
Summary
To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Fesoterodine
Criteria
Inclusion Criteria:

- Adult OAB patients who present with OAB symptoms, including micturitions >= 8 per day
and urinary urgency episodes >=1 per day.

Exclusion Criteria:

- Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or
to peanut or soya or any of the excipients.

- Patient has a known neurological disease influencing bladder function.

- Patient has a complication of lower urinary tract pathology potentially responsible
for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic
organ prolapse.